The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress

Mantle Cell Lymphoma MORE >>

Patients with mantle cell lymphoma who were treated with the combination of lenalidomide (Revlimid) and rituximab (Rituxan) continued to have durable responses and manageable side effects at 5 years of follow-up.

Latest JournalAll Journals >>

Evolving Paradigms Mantle Cell Lymphoma
Evolving Paradigms
MORE >>

The Targeted Oncology mantle cell lymphoma resource center serves as a hub for all clinical news and expert insights related to this rare subtype of non-Hodgkin lymphoma. Content found here includes video interviews with lymphoma experts and key opinion leaders in the field sharing their perspectives on existing mantle cell lymphoma treatment options and management approaches, including case studies that describe the clinical presentation and diagnostic criteria for patients with MCL.

This page also houses the most recent issue of Evolving Paradigms: Mantle Cell Lymphoma. This educational journal offers information regarding mantle cell lymphoma prognosis, staging, and risk, as well as current and emerging therapies for the disease.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.